Outcome of patients with localized prostate cancer treated by radiotherapy after confirming the absence of lymph node invasion

Japanese Journal of Clinical Oncology

Volumn 40, Issue 7, 2010, Pages 652-657

  Suzuki, Noriyuki ^a   Shimbo, Masaki ^a   Amiya, Yoshiyasu ^a   Tomioka, Susumu ^a   Shima, Takayuki ^a   Murakami, Shino ^a   Nakatsu, Hiroomi ^a   Oota, Sayako ^a   Shimazaki, Jun ^b  

^a ASAHI GENERAL HOSPITAL   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

Biochemical failure; High risk; Prostate cancer; PSA doubling time; Radiotherapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CHEMICAL ANALYSIS; CONTROLLED STUDY; HIGH RISK PATIENT; HORMONAL THERAPY; HUMAN; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; PHOTON THERAPY; PROSTATE CANCER; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 77954429782     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq032     Document Type: Article

References (30)

1. Hanks GE, Krall JM, Hanlon AL, Asbell SO, Pilepich MV, Owen JB. Patterns of care and RTOG studies in prostate cancer: Long term survival, Hazard rate observations, and possibilities of cure. Int J Radiat Oncology Biol Phys 1993;28:39-45.
2. Roach MIII, Marquez C, You H-S, Narayan P, Coleman L, Nseyo UO, et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncology Biol Phys 1993;28:33-7.
3. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001;58:843-8.
4. Nguyen PL, Chen M-H, Hoffman KE, Katz MS, D'Amico AV. Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era. Int J Radiat Oncology Biol Phys 2009;74:104-9.
5. Bhojani N, Ahyal S, Graefen M, Capitanio U, Suardi N, Shariat SF, et al. Partin tables cannot accurately predict the pathological stage at radical prostatectomy. Eur J Surg Oncol 2009;35:123-8.
6. Aizer AA, Yu JB, McKeon AM, Decker RH, Colberg JW, Peschel RE. Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma. Int J Radiat Oncology Biol Phys 2009;74.
7. NCCN Clinical Practice Guidelines in Oncology V2, 2009. www.nccn.org.
8. Abramowitz MC, Li T, Buyyounouski MK, Ross E, Uzzo RG, Pollack A, et al. The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer 2007;112:55-60.
9. Epstein JI, Allsbrook WC, Amin MB, Egevad LL, ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostate carcinoma. Am J Surg Pathol 2005;29:1228-41.
10. Schmid H-P, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing Cancer volume. Cancer 1993;71:2031-40.
11. Connolly D, Black A, Murray LJ, Napolitano G, Gavin A, Keane PF. Methods of calculating prostate-specific antigen velocity. Eur Urol 2007;52:1044-51.
12. Cheng L, Zincke H, Blute ML, Bergstralh EJ, Schere B, Bostwick DG. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 2001;91:66-73.
13. Boormans JL, Wildhagen MF, Bangma CH, Verhagen PC, van Leenders GJ. Histopathological characteristics of lymph node metastases predict cancer-specific survival in node-positive prostate cancer. BJU Int 2008;102:1589-93.
14. Vargas CE, Galalae R, Demanes J, Harsolia A, Meldolesi E, Nurnberg N, et al. Lack of benefit of pelvic radiation in prostate cancer patients with a high risk of positive pelvic lymph nodes treated with high-dose radiation. Int J Radiat Oncology Biol Phys 2005;63:1474-82.
15. Jacob R, Hanlon A, Horwitz M, Movsas B, Uzzo RG, Pollack A. Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement. Int J Radiat Oncology Biol Phys 2005;61:695-701.
16. Karakiewicz PI, Bhojan N, Capitanio U, Reuther AM, Suardi N, Jeldres C, et al. External validation of the updated Partin tables in a cohort of North American men. J Urol 2008;180:898-902.
17. Link RE, Morton RA. Indications for pelvic lymphadenectomy in prostate cancer. Urol Clin North Am 2001;28:491-8.
18. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-74.
19. Morgan PB, Hanlon AL, Horwitz EM, Buyyounouski MK, Uzzo RG, Pollack A. Timing of biochemical failure and distant metastatic disease for low-, intermediate, and high risk prostate cancer after radiotherapy. Cancer 2007;110:68-80.
20. Weckermann D, Dorn R, Trefz M, Wagner T, Wawroschek F, Harzmann R. Sentinel lymph node dissection for prostate cancer: experience with more than 1000 patients. J Urol 2007;177:916-20.
21. Briganti A, Blute ML, Eastham JH, Graefen M, Heidenreich A, Karns JR, et al. Pelvic lymph node dissection in prostate cancer. Eur Urol 2009;55:1251-65.
22. Thames HD, Kuban DA, DeSilvio ML, Levy LB, Horwitz EM, Kupelian PA, et al. Increasing external beam dose for T1-T2 prostate cancer: effect on risk groups. Int J Radiat Oncology Biol Phys 2006;65:975-81.
23. Goldner G, Dimopoulos J, Krisits C, Potter R. Moderate dose escalation in three-dimensional conformal localized prostate cancer radiotherapy: Single-institutional experience in 398 patients comparing 66 Gy versus 70 Gy versus 74 Gy. Strahlenther Onkol 2009;185:438-45.
24. Zagars GK, von Eschenbach AC, Ayala AG. Prognostic factors in prostate cancer. Analysis of 874 patients treated with radiation therapy. Cancer 1993;72:1709-25.
25. Denham JW, Steigler A, Wilcox C, Lamb DS, Joseph D, Atkinson C, et al. Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival? Cancer 2009;115:4477-87.
26. Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg DF, Pollack A. What pretreatment prostate-specific antigen level warrants ong-term androgen deprivation? Int J Radiat Oncology Biol Phys 2005;61:1003-10.
27. Prout-Lima C, Taylor JMG, Williams S, Ankerst DP, Liu N, Kestin LL, et al. Determinations of change in prostate-specific antigen over time and its association with recurrence after external beam radiation therapy for prostate cancer in five large cohorts. Int J Radiat Oncology Biol Phys 2008;72:782-91.
28. Bria E, Cuppone F, Giannarelli D, Milella M, Ruggeri EM, Sperduti I, et al. Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer? Meta-analysis of randomized trials. Cancer 2009;115:3446-56.
29. Lawton CA, Bae K, Pilepich M, Hanks G, Shipley W. Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation therapy oncology group studies 85-31 86-10, and 92-02. Int J Radiat Oncology Biol Phys 2008;70:437-41.
30. Taylor LG, Canfield SE, XLPrasad D. Review of major adverse effects of androgen deprivation therapy in men with prostate cancer. Cancer 2009;115:2388-99.